Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hyperaldosteronism: early-phase trial registry
1 of 3 indexed Hyperaldosteronism trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Hyperaldosteronism: 3 US clinical trials tracked, 1 recruiting.
Hyperaldosteronism is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Brigham and Women's Hospital, running 1 of these trials.
Enrollment posture brief
Registry condition hyperaldosteronism
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Hyperaldosteronism lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hyperaldosteronism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hyperaldosteronism is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
National Cancer Institute (NCI)
NCT06246357
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Brigham and Women's Hospital
NCT05925569
A Study of CIN-107 in Adults With Primary Aldosteronism
AstraZeneca
NCT04605549
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hyperaldosteronism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hyperaldosteronism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hyperaldosteronism page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hyperaldosteronism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Brigham and Women's Hospital sponsors the most Hyperaldosteronism trials on record, review their full trial history before evaluating a specific study. See Brigham and Women's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperaldosteronism condition card totals 3 registered trials; most-linked intervention CIN-107 8 mg dosing; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.